AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
| Revenue (TTM) | $79.21M |
| Gross Profit (TTM) | $-111.79M |
| EBITDA | $-188.28M |
| Operating Margin | -692.00% |
| Return on Equity | -14.70% |
| Return on Assets | -9.99% |
| Revenue/Share (TTM) | $0.26 |
| Book Value | $3.09 |
| Price-to-Book | 1.71 |
| Price-to-Sales (TTM) | 20.39 |
| EV/Revenue | 15.62 |
| EV/EBITDA | 5.30 |
| Quarterly Earnings Growth (YoY) | 45.90% |
| Quarterly Revenue Growth (YoY) | 96.30% |
| Shares Outstanding | $305.38M |
| Float | $205.09M |
| % Insiders | 23.04% |
| % Institutions | 43.43% |
Volatility is currently contracting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions.
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026.
Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Lynn Seely to its Board of Directors.
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wednesday.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABCL and any ticker you trade — then tracks every position and per-strategy win rate.
